Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 (SLVO) Stock Price Today
Aura AI Summary
Key Stats
- -Market Cap
- -Volume
- Income / Options OverlaySector
- $107.4152W High
- $61.8152W Low
- -Typical Hold Time
- -Enterprise Value
- -Div Yield
- -Trading Activity
Track Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 (SLVO) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 has traded between a low of $61.81 and a high of $107.41, highlighting its annual price range. Buy and sell Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033
SLVO is an exchange-traded note issued by UBS AG that provides investors with exposure to the performance of a silver-based covered call strategy. The ETN tracks the daily return of the ISE Enhanced 100x Leveraged Silver ETN Index, which combines a long position in silver with a covered call strategy on the silver position. This strategy aims to generate current income from the option premiums, which can provide a buffer during sideways or slightly down markets for silver, but it also caps the potential gains from a significant rise in silver prices. As an ETN, it is subject to the credit risk of the issuer, UBS AG, and has an expiration date of April 21, 2033.
Most Recent News
Inovio advances DNA medicine pipeline with FDA review of INO-3107 and $18.3M funding secured
Inovio Pharmaceuticals is progressing its DNA medicine pipeline with its lead candidate INO-3107 for Recurrent Respiratory Papillomatosis under FDA accelerated review, targeting a decision by October 30, 2026. The company raised $18.3 million in fund...
Life360 director Morin Brit sells 15,582 shares for $1 million
Morin Brit, a director at Life360, sold 15,582 shares of the company, generating $1 million from the transaction. This sale may indicate a personal financial decision or portfolio adjustment by the director. Investors might watch for any further insi...
AbCellera's stock jumps after successful menopause drug trial and CFO insider buying.
AbCellera Biologics announced positive Phase 2 trial results for its experimental menopause drug ABCL635, which significantly reduced hot flash frequency by 83%. The stock surged 33.19% to a 52-week high of $11.32, boosting the company's market cap t...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.